Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,280 questions in 114 reviews · Cystic Fibrosis and Genetic Disorders
current versionsNo studies 856 · 37.5%Ungraded 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Autogenic drainage vs intrapulmonary percussive ventilation (200 bpm) Adverse events · adults with CF Autogenic drainage for airway clearance in cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Autogenic drainage vs intrapulmonary percussive ventilation (200 bpm) Number of admissions to hospital · adults with CF Autogenic drainage for airway clearance in cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Autogenic drainage vs intrapulmonary percussive ventilation (200 bpm) Need for extra treatment · adults with CF Autogenic drainage for airway clearance in cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Autogenic drainage vs intrapulmonary percussive ventilation (400 bpm) FEV1 % predicted (change from baseline) · adults with CF Autogenic drainage for airway clearance in cystic fibrosis (2021) · Cochrane | no estimate extracted | 1 study · 4 participants | Very low |
Autogenic drainage vs intrapulmonary percussive ventilation (400 bpm) QoL · adults with CF Autogenic drainage for airway clearance in cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Autogenic drainage vs intrapulmonary percussive ventilation (400 bpm) Participant preference · adults with CF Autogenic drainage for airway clearance in cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Autogenic drainage vs conventional physiotherapy Number of admissions to hospital · adults and children with CF Autogenic drainage for airway clearance in cystic fibrosis (2021) · Cochrane | no estimate extracted | 1 study · 36 participants | Very low |
Autogenic drainage vs intrapulmonary percussive ventilation (400 bpm) Exercise tolerance (modified shuttle test) · adults with CF Autogenic drainage for airway clearance in cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Autogenic drainage vs intrapulmonary percussive ventilation (400 bpm) Adverse events · adults with CF Autogenic drainage for airway clearance in cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Autogenic drainage vs intrapulmonary percussive ventilation (400 bpm) Number of admissions to hospital · adults with CF Autogenic drainage for airway clearance in cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Autogenic drainage vs intrapulmonary percussive ventilation (400 bpm) Need for extra treatment · adults with CF Autogenic drainage for airway clearance in cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Autogenic drainage vs conventional physiotherapy Need for extra treatment · adults and children with CF Autogenic drainage for airway clearance in cystic fibrosis (2021) · Cochrane | no estimate extracted | 1 study · 36 participants | Very low |
Autogenic drainage vs spontaneous cough FEV1 % predicted · adults and children with CF Autogenic drainage for airway clearance in cystic fibrosis (2021) · Cochrane | no estimate extracted | 1 study · 14 participants | Very low |
Autogenic drainage vs spontaneous cough QoL · adults and children with CF Autogenic drainage for airway clearance in cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR 12MWT: change from baseline in m walked · children and adults with mucopolysaccharidosis type VI Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI (2021) · Cochrane | no estimate extracted | 1 study · 38 participants | Very low |
Intervention NR 3MSC: change in 3MSC rates (stairs/min) from baseline · children and adults with mucopolysaccharidosis type VI Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI (2021) · Cochrane | no estimate extracted | 1 study · 38 participants | Very low |
Intervention NR 6MWT: change from baseline in m walked · children and adults with mucopolysaccharidosis type VI Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI (2021) · Cochrane | no estimate extracted | 1 study · 38 participants | Very low |
Intervention NR Respiratory tests: absolute change from baseline in FVC (L) · children and adults with mucopolysaccharidosis type VI Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI (2021) · Cochrane | no estimate extracted | 1 study · 38 participants | Very low |
Intervention NR Cardiac function  · children and adults with mucopolysaccharidosis type VI Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI (2021) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR GAG level: change in urinary GAG level from baseline ųg/mg creatinine · children and adults with mucopolysaccharidosis type VI Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI (2021) · Cochrane | no estimate extracted | 1 study · 38 participants | Low |
Intervention NR AEs: drug‐related AEs · children and adults with mucopolysaccharidosis type VI Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI (2021) · Cochrane | RR 1.93 [0.89, 4.17] | 1 study · 39 participants | Very low |
Cisapride vs placebo Radiological diagnosis of DIOS (physician‐measured radiological scores) · people with cystic fibrosis Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis (2021) · Cochrane | no estimate extracted | 1 study · 17 participants | Very low |
Cisapride vs placebo Adverse effects (participant interviews) · people with cystic fibrosis Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis (2021) · Cochrane | no estimate extracted | 1 study · 17 participants | Very low |
Cisapride vs placebo Total gastrointestinal symptom scores (participant‐reported symptom scores from 20 to 100) · people with cystic fibrosis Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis (2021) · Cochrane | no estimate extracted | 1 study · 17 participants | Very low |
Cisapride vs placebo Hospitalisation for any cause · people with cystic fibrosis Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Cisapride vs placebo Hospitalisation for DIOS · people with cystic fibrosis Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Cisapride vs placebo Quality of life · people with cystic fibrosis Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Cisapride vs placebo Tolerability · people with cystic fibrosis Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ high‐dose pancreatic enzymes vs low‐dose pancreatic enzymes Time taken from start of treatment until the resolution of DIOS · children and adults with cystic fibrosis Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ high‐dose pancreatic enzymes vs low‐dose pancreatic enzymes Treatment failure rate · children and adults with cystic fibrosis Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ high‐dose pancreatic enzymes vs low‐dose pancreatic enzymes Adherence · children and adults with cystic fibrosis Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ high‐dose pancreatic enzymes vs low‐dose pancreatic enzymes Episodes of acute DIOS · children and adults with cystic fibrosis Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis (2021) · Cochrane | no estimate extracted | 1 study · 20 participants | Very low |
Summary of findings ‐ high‐dose pancreatic enzymes vs low‐dose pancreatic enzymes Adverse effects: abdominal mass · children and adults with cystic fibrosis Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis (2021) · Cochrane | no estimate extracted | 1 study · 20 participants | Very low |
Summary of findings ‐ high‐dose pancreatic enzymes vs low‐dose pancreatic enzymes Adverse effects: abdominal pain · children and adults with cystic fibrosis Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis (2021) · Cochrane | no estimate extracted | 1 study · 20 participants | Very low |
Summary of findings ‐ AZLI vs placebo Relative change in FEV1% predicted · adults and children with CF Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis (2021) · Cochrane | no estimate extracted | 1 study · 99 participants | Moderate |
Summary of findings ‐ AZLI vs placebo Days to next exacerbation · adults and children with CF Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis (2021) · Cochrane | no estimate extracted | 1 study · 100 participants | Moderate |
Summary of findings ‐ AZLI vs placebo Participants hospitalised for respiratory exacerbation · adults and children with CF Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis (2021) · Cochrane | RR 0.88 [0.53, 1.45] | 1 study · 100 participants | Moderate |
Summary of findings ‐ AZLI vs placebo Any AEs · adults and children with CF Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis (2021) · Cochrane | RR 1.08 [0.98, 1.19] | 1 study · 100 participants | Moderate |
Summary of findings ‐ AZLI vs placebo Mortality · adults and children with CF Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis (2021) · Cochrane | RR 5.41 [0.27, 109.87] | 1 study · 100 participants | Moderate |
Intervention NR Number of joint bleeding episodes per year (AJBR) · children or adults with hemophilia A or B Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously… (2021) · Cochrane | no estimate extracted | 3 studies · 219 participants | Low |
Intervention NR Number of total bleeds per year (ABR) · children or adults with hemophilia A or B Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously… (2021) · Cochrane | no estimate extracted | 7 studies · 310 participants | Low |
Intervention NR Treatment‐related adverse events · children or adults with hemophilia A or B Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously… (2021) · Cochrane | no estimate extracted | 3 studies · 223 participants | Very low |
Prophylaxis with standard therapeutic factor concentrate vs pegylated liposome FVIII formulation AJBR · children or adults with hemophilia A Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously… (2021) · Cochrane | no estimate extracted | 1 study · 143 participants | Low |
Prophylaxis with standard therapeutic factor concentrate vs pegylated liposome FVIII formulation ABR · children or adults with hemophilia A Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously… (2021) · Cochrane | no estimate extracted | 1 study · 143 participants | Low |
Prophylaxis with standard therapeutic factor concentrate vs pegylated liposome FVIII formulation Any reported adverse effects · children or adults with hemophilia A Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously… (2021) · Cochrane | no estimate extracted | 1 study · 143 participants | Low |
Prophylaxis regimen vs on‐demand treatment Number of joint bleeding episodes or joint bleeding frequency · children and adults with haemophilia A or B Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously… (2021) · Cochrane | no estimate extracted | 2 studies · 164 participants | Low |
Prophylaxis regimen vs on‐demand treatment Number of total bleeds per year or bleeding frequency · children and adults with haemophilia A or B Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously… (2021) · Cochrane | no estimate extracted | 2 studies · 164 participants | Low |
Prophylaxis regimen vs on‐demand treatment Any reported adverse events · children and adults with haemophilia A or B Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously… (2021) · Cochrane | RR 1.71 [1.24, 2.37] | 2 studies · 131 participants | Moderate |
Summary of findings ‐ Prophylactic vs 'as required' anti‐staphylococcal antibiotics FEV1 (% predicted (Knudson 1983)) · children with cystic fibrosis Prophylactic anti‐staphylococcal antibiotics for cystic fibrosis (2020) · Cochrane | no estimate extracted | 1 study · 119 participants | Low |
Summary of findings ‐ Prophylactic vs 'as required' anti‐staphylococcal antibiotics Number of people with one or more isolates of S aureus (sensitive strains) · children with cystic fibrosis Prophylactic anti‐staphylococcal antibiotics for cystic fibrosis (2020) · Cochrane | OR 0.21 [0.13, 0.35] | 3 studies · 315 participants | Low |